Information  X 
Enter a valid email address

Alliance Pharma PLC (APH)

  Print      Mail a friend       Annual reports

Wednesday 08 April, 2020

Alliance Pharma PLC

Block Admission Application

RNS Number : 1349J
Alliance Pharma PLC
08 April 2020
 

For immediate release

8 April 2020

 

 

 

 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

 

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces that it has applied for a block admission for a further 15,000,000   ordinary shares of 1p each in the Company ("Ordinary Shares") to be admitted to trading on AIM on 9 April 2020. This will be used to facilitate the admission of shares to trading following the exercise of options granted under the following two employee share schemes:

 

· The Alliance Pharma plc Approved Share Option Plan 2005 (up to 160,000 shares);

· The Alliance Pharma plc Company Share Option Plan 2015 (up to 14,840,000 shares).

 

The Company will make six-monthly announcements of the utilisation of the block admission, in line with its obligations under AIM Rule 29.

 

New Ordinary Shares issued following option exercises and admitted to trading under the block admission will rank pari passu in all respects with the existing Ordinary Shares.

 

At the time of this announcement, Alliance has   530,269,365 Ordinary Shares in issue.

 

For further information:

 

Alliance Pharma plc    + 44 (0) 1249 466966

Peter Butterfield, Chief Executive Officer

Andrew Franklin, Chief Financial Officer

www.alliancepharma.co.uk  

 

Buchanan      + 44 (0) 20 7466 5000

Mark Court / Sophie Wills / Hannah Ratcliff

 

Numis Securities Limited      + 44 (0) 20 7260 1000

Nominated Adviser: Freddie Barnfield

Corporate Broking: James Black

 

Investec Bank plc    +44 (0) 20 7597 5970

Corporate Finance: Daniel Adams / Ed Thomas

Corporate Broking: Patrick Robb / Tejas Padalkar

 

Notes to editors:

 

About Alliance Pharma

Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with subsidiaries in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating revenues in more than 100 countries.

 

We currently own or license the rights to around 90 consumer healthcare products and pharmaceuticals, which are managed on a portfolio basis according to their growth potential. Promotional investment is focused on a small number of brands with significant international or multi-territory reach. The remainder of the portfolio comprises products which are sold in a limited number of local markets and require little or no promotional investment.

Our strategy allows us to deliver good organic growth and to enhance our growth rate through carefully selected acquisitions.

For more information on Alliance, please visit our website www.alliancepharmaceuticals.com


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ALSFZGGDGNGGGZZ

a d v e r t i s e m e n t